Dong-A looks forward to achieving the top pharmaceutical company with its 4 new drugs
The Dong-A ST’s constant R&D investment and effort launched the 24th domestic new drug.
Dong-A ST (CEO and President Chan-il Park) announced on the 17th that its first FDA-approve super bacteria antibiotic ‘Sivextro (generic name: tedizolid)’ has been approved for a domestic new drug from the Mi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
